Who Should NOT Take GLP-1 Weight Loss Medication
GLP-1 drugs like semaglutide and tirzepatide are not for everyone. Here's an honest list of who should not take them, and why — from contraindications to caution cases.
Most articles about GLP-1 weight management drugs are written for the people who *can* take them. This article is about the people who can't, or shouldn't, or should at least talk seriously to their doctor before starting. It is shorter than the "benefits" articles. That is deliberate. If any of these conditions apply to you, that is information that should shape your next conversation with a healthcare provider.
This is not meant to scare anyone off GLP-1 medications. For millions of patients, they are safe and effective. But "safe for most" is not the same as "safe for all", and the population of people for whom these drugs are not appropriate is meaningful.
Absolute contraindications (per the FDA and EMA labels)
These are the conditions where the official drug labels — the ones approved by the FDA in the US and the EMA in Europe — explicitly say: do not prescribe this drug.
1. Personal or family history of medullary thyroid carcinoma (MTC)
Semaglutide, tirzepatide, liraglutide, and dulaglutide all carry a boxed warning (the FDA's most serious warning level) about medullary thyroid carcinoma. This came from rodent studies in which GLP-1 agonists caused thyroid C-cell tumours. Whether that translates to human risk is not clear — humans have very few thyroid C-cells compared to rodents, and long-term human data has not replicated the finding — but regulators decided the warning was appropriate.
In practice, this means:
This is a small group of people, but if you are in it, the answer is firm.
2. Known hypersensitivity to semaglutide or other excipients
If you have had a serious allergic reaction (anaphylaxis, angioedema) to semaglutide or to any of the inactive ingredients in the formulation, you cannot take it again. This is rare but it happens.
Strong cautions — talk to your doctor, do not self-prescribe
These are not absolute no-gos, but they are conditions where starting a GLP-1 drug requires a real conversation with a real doctor, not an internet order form.
3. History of pancreatitis
Pancreatitis has been reported as a rare but serious adverse event with GLP-1 drugs. Large observational studies have been mixed on whether the drugs actually *cause* pancreatitis or whether the association is confounded by obesity and diabetes (both of which independently increase pancreatitis risk). Either way, if you have had acute or chronic pancreatitis in the past, your doctor needs to know before prescribing.
If you develop severe, persistent abdominal pain that radiates to the back while on a GLP-1 drug, stop taking it and seek medical attention immediately. That is a red-flag symptom for acute pancreatitis.
4. Severe gastrointestinal disease — especially gastroparesis
Because GLP-1 drugs slow gastric emptying, they can worsen conditions in which gastric emptying is already impaired. Gastroparesis (a condition where the stomach doesn't empty normally, often seen in long-standing diabetes) is the clearest case. Patients with severe gastroparesis generally should not be on GLP-1 drugs — or at the very least, should be managed very carefully by a gastroenterologist.
Other conditions that deserve a conversation: severe gastroesophageal reflux, inflammatory bowel disease in an active flare, a history of bowel obstruction.
5. Pregnancy, attempting to conceive, or breastfeeding
GLP-1 drugs are not recommended during pregnancy or breastfeeding. The data in pregnancy is limited, animal studies have shown some concerning signals, and weight loss during pregnancy is generally not appropriate anyway. Official guidance is to stop GLP-1 drugs at least 2 months before attempting to conceive, because the drug takes time to clear your system.
If you are pregnant, thinking of becoming pregnant, or breastfeeding, a GLP-1 drug is not the right choice right now. Revisit it with your doctor after you are done with the pregnancy and breastfeeding phase.
6. Type 1 diabetes
GLP-1 drugs are approved and designed for type 2 diabetes, not type 1. In type 1, the pancreas has largely stopped making insulin, and GLP-1's mechanism (stimulating insulin release from beta cells) doesn't work the same way. There is research on off-label use in type 1 as an adjunct to insulin, but this is experimental and should only happen under specialist supervision.
7. Severe kidney or liver impairment
This one is more nuanced than "adjust the dose." Neither drug's FDA label sets a dose adjustment for kidney or liver impairment, but the two labels do not say the same thing. Tirzepatide's (Zepbound, revised September 2026) states that renal impairment, including end-stage renal disease, and hepatic impairment do not change its pharmacokinetics, and recommends no dosage adjustment for either. Semaglutide's (Wegovy, revised June 2026) reports no clinically significant pharmacokinetic difference for mild-to-moderate kidney impairment (eGFR 30 to below 90) or mild-to-severe liver impairment (Child-Pugh A to C) — it makes no such statement for an eGFR below 30 or dialysis, where trial experience is small (the label counts 65 trial participants with a history of moderate or severe renal impairment), and it notes that gastrointestinal reactions were more frequent in patients with a history of renal impairment. So the real caution is not a dosing rule: the drugs' own GI side effects — nausea, vomiting, diarrhoea — can cause dehydration that worsens kidney function; both labels carry postmarketing reports of acute kidney injury, some requiring haemodialysis, and both tell prescribers to monitor kidney function in anyone reporting reactions that could cause volume depletion. If you have severely impaired kidney function or advanced liver disease, that is a conversation for a specialist, not a dosing footnote.
8. History of certain eating disorders
This is a newer area of caution. GLP-1 drugs suppress appetite profoundly, and in patients with a history of anorexia nervosa, bulimia, or other restrictive eating disorders, that suppression can be dangerous. Some clinicians now consider active or recent history of restrictive eating disorder to be a contraindication. If this applies to you, a general practitioner probably isn't the right person to manage a GLP-1 prescription — you'd want someone who specialises in eating disorder medicine.
Caution: children and adolescents
Semaglutide (Wegovy) has been approved for adolescents aged 12 and over in some jurisdictions, but this is a space where the evidence base is still developing and prescribing should happen through paediatric specialists, not adult weight-management platforms. This is not the same as "safe for adults".
What about psychiatric conditions?
This is worth a mention because it comes up a lot. Early reports after the rise of GLP-1 drugs suggested possible links to depression, suicidal ideation, or other mood changes. Large subsequent analyses (including an FDA review) have not found a clear causal link — the background rates of depression in obese and diabetic populations are already elevated, which makes the signal hard to interpret. However:
The meta-point
The reason these drugs are prescription-only in every major regulated market — India, Brazil, the EU, Canada, the US, the UK, Australia — is because the decision of whether you should be on one requires a real medical assessment of your individual history. Internet-only telehealth services that prescribe GLP-1 drugs after a 2-minute form are, charitably, cutting corners. The contraindications above are not fringe edge cases. They are real, and missing them can cause real harm.
If you are considering a GLP-1 drug, a proper consultation with a qualified doctor — one who asks about your family history, your past GI conditions, your mental health, and your medication list — is the minimum standard of care. If a service is not offering that, it is not offering medicine. It is offering a transaction.
This article is educational and not a substitute for medical advice. Speak to a licensed healthcare provider before starting or changing any medication.
Related reading:
Have questions about GLP-1 access in India? Learn more about Magistra India or read our FAQ.
See your own numbers
Our free predictor estimates your side-effect risk and weight trajectory, with the stated rates and distinct sources shown behind every figure. No signup required.
Open the predictorWorking from the data itself? The dated snapshot behind these figures is available as a one-off purchase, alongside the free public API: Data & API.